Abstract
The arsenal of drugs in the fight against AIDS is rapidly diminishing as the HIV becomes resistant to the available reverse transcriptase and protease inhibitors. After killing millions all over the world, the virus is still on the rampage and hence the pharmaceutical industry is resorting to the development of inhibitors of integrase. This seems to be the last arrow in the quiver of potential drug leads to combat the deadly infection. Several classes of HIV integrase inhibitors have been reported to date; however, none is clinically useful. This review details the existing knowledge of the biological functions of the HIV-1 integrase with the focus on its available inhibitors, their disadvantages, and the current trends in designing novel compounds as antiintegrase.
Keywords: Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV), retroviral integrase, antiviral agent
Current Medicinal Chemistry
Title: Designing HIV Integrase Inhibitors-Shooting the Last Arrow
Volume: 13 Issue: 20
Author(s): Mahindra T. Makhija
Affiliation:
Keywords: Acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus (HIV), retroviral integrase, antiviral agent
Abstract: The arsenal of drugs in the fight against AIDS is rapidly diminishing as the HIV becomes resistant to the available reverse transcriptase and protease inhibitors. After killing millions all over the world, the virus is still on the rampage and hence the pharmaceutical industry is resorting to the development of inhibitors of integrase. This seems to be the last arrow in the quiver of potential drug leads to combat the deadly infection. Several classes of HIV integrase inhibitors have been reported to date; however, none is clinically useful. This review details the existing knowledge of the biological functions of the HIV-1 integrase with the focus on its available inhibitors, their disadvantages, and the current trends in designing novel compounds as antiintegrase.
Export Options
About this article
Cite this article as:
Makhija T. Mahindra, Designing HIV Integrase Inhibitors-Shooting the Last Arrow, Current Medicinal Chemistry 2006; 13(20) . https://dx.doi.org/10.2174/092986706777935096
DOI https://dx.doi.org/10.2174/092986706777935096 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Clinical Next Generation Sequencing for Precision Medicine in Cancer
Current Genomics Effect of Formulations of Nanosized Quercetin Liposomes on COX-2 and NF-kB in MCF-10A Cells
Pharmaceutical Nanotechnology Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Current Genomics Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Retinoids in Clinical Use
Medicinal Chemistry Editorial: Overview on microRNAs in Cancer Development and Virus Infection
MicroRNA The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Techniques and Strategies to Analyze Neural Progenitor Cell Migration
Current Pharmaceutical Biotechnology Autophagy : Moving Benchside Promises to Patient Bedsides
Current Cancer Drug Targets Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Solvent Modulation of Column Chromatography
Protein & Peptide Letters Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Current Topics in Medicinal Chemistry Application of Charge Transfer Reactions for the Quantitative Spectrophotometric Determination of Cyclophosphamide in Pure and Pharmaceutical Formulation
Current Pharmaceutical Analysis Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Recent Progress in the Development of Histone Deacetylase Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Current Cancer Drug Targets Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry